Payment overview · 2025
General Payments
$109.34
6 reported records · 5 companies
Healthcare provider profile · identity verified
Michael L Matthews, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SIDNEY, NE · NPI 1821177726
Verified facts
What the public records show
CMS Open Payments records show Michael L Matthews, M.D. received $109.34 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.33 | 31.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.30 | 20.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.26 | 18.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $17.00 | 15.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.45 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.34 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.33 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 630 | 120 |
| Lisinopril | Lisinopril | 435 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 96 |
| Omeprazole | Omeprazole | 393 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 376 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 57 |
| Gabapentin | Gabapentin | 289 | 60 |
| Losartan Potassium | Losartan Potassium | 248 | 56 |
| Tramadol Hcl | Tramadol Hcl | 216 | 55 |
| Montelukast Sodium | Montelukast Sodium | 208 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 54 |
| Eliquis | Apixaban | 201 | 30 |
| Potassium Chloride | Potassium Chloride | 201 | 45 |
| Furosemide | Furosemide | 185 | 42 |
| Metformin Hcl | Metformin Hcl | 183 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 182 | 39 |
| Allopurinol | Allopurinol | 162 | 27 |
| Meloxicam | Meloxicam | 155 | 34 |
| Sertraline Hcl | Sertraline Hcl | 147 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 38 |
| Simvastatin | Simvastatin | 138 | 32 |
| Warfarin Sodium | Warfarin Sodium | 124 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 26 |
| Pregabalin | Pregabalin | 116 | 21 |
| Trazodone Hcl | Trazodone Hcl | 112 | 24 |
| Jardiance | Empagliflozin | 105 | 13 |
| Ozempic | Semaglutide | 99 | 15 |
| Prednisone | Prednisone | 96 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 22 |
| Spironolactone | Spironolactone | 82 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 20 |
| Alprazolam | Alprazolam | 74 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 12 |
| Buspirone Hcl | Buspirone Hcl | 71 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 67 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 14 |
| Carvedilol | Carvedilol | 62 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 14 |
| Metformin Hcl Er | Metformin Hcl | 57 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | suppressed |
| Baclofen | Baclofen | 56 | 11 |
| Celecoxib | Celecoxib | 55 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 54 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 51 | suppressed |
| Mirtazapine | Mirtazapine | 49 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 12 |
| Famotidine | Famotidine | 43 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 27 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Finasteride | Finasteride | 41 | 11 |
| Lorazepam | Lorazepam | 41 | 16 |
| Trulicity | Dulaglutide | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 36 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | 16 |
| Atenolol | Atenolol | 30 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 16 |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Cefdinir | Cefdinir | 24 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine | Lidocaine | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.34 · 6 records | Lilly USA, LLC | LEQVIO, MOUNJARO, Ozempic, VRAYLAR, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error